metricas
covid
Buscar en
Archivos de la Sociedad Española de Oftalmología (English Edition)
Toda la web
Inicio Archivos de la Sociedad Española de Oftalmología (English Edition) Intralesional rituximab in primary conjunctival follicular lymphoma relapsed
Journal Information
Vol. 92. Issue 7.
Pages 326-329 (July 2017)
Share
Share
Download PDF
More article options
Visits
8
Vol. 92. Issue 7.
Pages 326-329 (July 2017)
Short communication
Intralesional rituximab in primary conjunctival follicular lymphoma relapsed
Rituximab intralesional como tratamiento de linfoma folicular primario de conjuntiva recidivante
Visits
8
S. Rodríguez Villaa,
Corresponding author
susanarodriguezvilla@gmail.com

Corresponding author.
, M.J. Ruiz Rodríguezb, M. Vargas Pabónc
a Servicio de Oftalmología, Hospital Universitario de Cabueñes, Gijón, Asturias, Spain
b Servicio de Oftalmología, Hospital Comarcal Jarrio, Coaña, Asturias, Spain
c Servicio de Hematología, Hospital Comarcal Jarrio, Coaña, Asturias, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Abstract
Clinical case

A 49-year-old woman experienced a local relapse of a primary follicular lymphoma (FL) of the conjunctiva. She received 4 weekly intra-lesional injections followed by 6 monthly injections of rituximab (6mg/ml). A clinical response was achieved after first injection. No adverse ocular event or signs of lymphoma relapse were seen after 10 months of follow-up.

Discussion

Intralesional administration of rituximab for treating primary FL of the conjunctiva was an effective and safe therapeutic option; therefore it could be an alternative to other conventional treatments, such as radiotherapy or chemotherapy.

Keywords:
Rituximab
Intralesional rituximab
Follicular lymphoma
Conjunctival lymphoma
Conjunctival tumor
Ocular adnexal lymphoma
Resumen
Caso clínico

Mujer de 49 años que presenta recidiva de un linfoma folicular (LF) primario de conjuntiva. Se realiza inyección subconjuntival de rituximab intralesional de 6mg/ml, semanalmente durante 4 semanas, seguido de una administración mensual durante 6 meses. Tras la primera inyección se observa disminución del tejido linfoide. A los 10 meses del seguimiento no se observa recidiva de linfoma ni se aprecian efectos adversos.

Discusión

Rituximab intralesional como tratamiento del LF primario de conjuntiva resultó efectivo y seguro, por lo que podría ser una alternativa a otras opciones terapéuticas convencionales como la radioterapia o la quimioterapia.

Palabras clave:
Rituximab
Tratamiento intralesional
Linfoma folicular
Linfoma de la conjuntiva
Tumor de la conjuntiva
Linfoma de anejos oculares

Article

These are the options to access the full texts of the publication Archivos de la Sociedad Española de Oftalmología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Archivos de la Sociedad Española de Oftalmología (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos